Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT00981084

Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study

Sponsor: University of Kansas

Conditions Multiple Sclerosis

Interventions armodafinil

Updated 7 times since 2017 Last updated: Aug 6, 2013 Started: Sep 30, 2009 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Multiple Sclerosis and is currently completed. University of Kansas leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Kansas
University of Missouri, Kansas City

Data source: University of Missouri, Kansas City

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kansas City, United States